Knight Therapeutics (GUD) EPS Estimated At $0.04, Fibrocell Science (FCSC) Had 4 Analysts Last Week

July 18, 2017 - By Nellie Frank

Among 5 analysts covering Fibrocell Science (NASDAQ:FCSC), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Fibrocell Science had 5 analyst reports since September 28, 2015 according to SRatingsIntel. As per Friday, June 9, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by TH Capital given on Tuesday, December 22. The rating was initiated by Roth Capital with “Buy” on Tuesday, December 22. The firm has “Neutral” rating given on Monday, September 28 by Wedbush. See Fibrocell Science Inc (NASDAQ:FCSC) latest ratings:

09/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.7000 Maintain
07/03/2017 Broker: Rodman & Renshaw Rating: Buy New Target: $2.00 Initiates Coverage On

Analysts expect Knight Therapeutics Inc (TSE:GUD) to report $0.04 EPS on August, 10.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.04 EPS. T_GUD’s profit would be $5.70 million giving it 61.88 P/E if the $0.04 EPS is correct. After having $0.04 EPS previously, Knight Therapeutics Inc’s analysts see 0.00% EPS growth. The stock increased 0.05% or $0.01 on July 17, reaching $9.9. About shares traded. Knight Therapeutics Inc (TSE:GUD) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock decreased 2.79% or $0.11 on July 17, reaching $3.83. About shares traded. Fibrocell Science Inc (NASDAQ:FCSC) has declined 57.80% since July 18, 2016 and is downtrending. It has underperformed by 74.50% the S&P500.

Investors sentiment decreased to 0.47 in Q4 2016. Its down 0.03, from 0.5 in 2016Q3. It dived, as 8 investors sold Fibrocell Science Inc shares while 9 reduced holdings. 2 funds opened positions while 6 raised stakes. 23.97 million shares or 3.70% less from 24.89 million shares in 2016Q3 were reported. Third Security holds 0.56% or 16.62M shares in its portfolio. Staley Cap Advisers holds 0.01% or 98,500 shares. Tci Wealth Advsrs has 0% invested in Fibrocell Science Inc (NASDAQ:FCSC). Vanguard Group Inc reported 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Bancshares Of New York Mellon reported 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Value Ltd Liability Co reported 47,769 shares. Blackrock Fund holds 0% or 62,925 shares in its portfolio. Northern Corp reported 0% stake. Wells Fargo And Mn holds 3,025 shares. Franklin Street Advsr Nc holds 0.01% or 50,000 shares. 25,281 were accumulated by Morgan Stanley. Fmr Llc holds 2.61 million shares or 0% of its portfolio. Goldman Sachs Group Inc invested 0% in Fibrocell Science Inc (NASDAQ:FCSC). Walleye Trading Limited Liability Company has invested 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Kcg Holding Incorporated stated it has 63,087 shares or 0% of all its holdings.

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has market cap of $61.77 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Knight Therapeutics Inc is a Canada pharmaceutical company. The company has market cap of $1.41 billion. The Firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It has a 54.1 P/E ratio. It finances other life sciences companies in Canada and internationally.

Among 2 analysts covering Knight Therapeutics (TSE:GUD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Knight Therapeutics had 11 analyst reports since May 12, 2016 according to SRatingsIntel. TD Securities maintained the shares of GUD in report on Friday, March 17 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: